Canary Bio is a specialized biotechnology firm that focuses on creating novel anticancer medications and possesses research assets dedicated to immunotherapy drug development. The company, along with its subsidiaries, has a robust pipeline for innovating various immunotherapy drugs targeting ovarian cancer, pancreatic cancer, and metastatic breast cancer. The notable achievements include FLORA-5 (oregobomab), which garnered significant attention in prestigious gynecological cancer journals due to its exceptional results in a phase 2 clinical trial.